<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873570</url>
  </required_header>
  <id_info>
    <org_study_id>CB-034-MOX(M)-2020</org_study_id>
    <nct_id>NCT04873570</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects</brief_title>
  <acronym>BE</acronym>
  <official_title>A Single Center, Open Label, Randomized, Single-dose, Two-period, Two-way Cross-over Study to Compare the Rate and Extent of Absorption of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Karachi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SAMI Pharmaceutical, Karachi Pakistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Bioequivalence Studies and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Karachi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single oral dose, of test and reference Tablet will be administered to healthy volunteers,&#xD;
      after at least 10 hours fast together with 240 mL of ambient temperature water at their&#xD;
      scheduled dosing time-points. Blood samples will be taken up to 72.0 hours post-dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A single center, open label, randomized, single-dose, two-period, two-way cross-over study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum plasma concentration</measure>
    <time_frame>up to 72 hours post dose</time_frame>
    <description>maximum drug concentration in plasma after dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration</measure>
    <time_frame>0 to 72 hours post dose</time_frame>
    <description>Time required for the drug to reach maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Area under the time versus plasma drug concentration curve</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Individuals</condition>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be given one Mofest® 400mg (Moxifloxacin HCl) Tablet (1x400mg) manufactured by SAMI Pharmaceuticals (Pvt.) after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400mg</intervention_name>
    <description>Moxifloxacin 400mg IR tablet</description>
    <arm_group_label>Reference Group</arm_group_label>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects aged 18 to 55 years inclusive.&#xD;
&#xD;
          -  Subjects with a body mass index (BMI) from 18.5 to 30 kg/m2.&#xD;
&#xD;
          -  Subject is able to fast for 14 hours and consume standard meals.&#xD;
&#xD;
          -  Subjects who are healthy as determined by routine physical examination, including&#xD;
             vital sign monitoring (i.e., blood pressure, heart rate, and temperature), 12-Lead&#xD;
             ECG, and safety laboratory analysis (i.e., hematology, blood biochemistry, and&#xD;
             urinalysis) or viral serology as determined by the investigator.&#xD;
&#xD;
          -  Subjects should have negative urine test for drugs of abuse (morphine &amp; cannabinoids&#xD;
             will be tested) and alcohol breath analysis at screening and prior to each check-in.&#xD;
&#xD;
          -  Subjects who are able to, understand and sign the Informed Consent Form for Medical&#xD;
             Screening during their screening visit and Participation Informed Consent Form on&#xD;
             study check-In day.&#xD;
&#xD;
          -  Subject agreed not to consume food or beverages including dairy products, tea, coffee,&#xD;
             cola drinks, chocolates containing xanthine derivatives (including caffeine,&#xD;
             theobromines, etc.) and/or poppy seeds (Khash khash) within 48 hours prior to drug&#xD;
             administration until last blood draw in each study period.&#xD;
&#xD;
          -  Subject agreed not to intake prescription drugs (especially amiodarone, carbamazepine,&#xD;
             Antacids (aluminum and magnesium hydroxides) NSAIDS, digoxin and Blood thinners such&#xD;
             as warfarin, etc.) within 14 days or 5 half-lives (whichever is longer) prior to first&#xD;
             dose of study medicine.&#xD;
&#xD;
          -  Subject agreed not to intake non-prescription drugs (OTC) within 14 days prior to&#xD;
             first dose of study medicine.&#xD;
&#xD;
          -  Subject agreed to discontinue vitamins, dietary and herbal supplements within 14 days&#xD;
             prior to the first dose of study medication.&#xD;
&#xD;
          -  Subject agreed not to consume grapefruit and/or its products within 14 days prior to&#xD;
             the start of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who refused to sign Informed Consent Form.&#xD;
&#xD;
          -  Subject not able to take medicine orally.&#xD;
&#xD;
          -  Pregnant and lactating females.&#xD;
&#xD;
          -  History of smoking ≥3 cigarette/day, alcoholism, and positive test for drug of abuse,&#xD;
             heavy pan or gutka user as judged by teeth / mouth inspection.&#xD;
&#xD;
          -  Subject has clinically relevant evidence of cardiovascular, gastrointestinal/hepatic,&#xD;
             renal, psychiatric, respiratory, urogenital, hematological/immunologic, HEENT (head,&#xD;
             ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal,&#xD;
             metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or&#xD;
             other relevant diseases as revealed by medical history, physical examination, and&#xD;
             laboratory assessments which may interfere with the absorption, distribution,&#xD;
             metabolism or elimination of drugs or constitute a risk factor when taking study&#xD;
             medication.&#xD;
&#xD;
          -  Subjects known to be allergic to Moxifloxacin and/or other Quinolones antibiotics&#xD;
&#xD;
          -  Subject who has received any other investigational drug within four weeks.&#xD;
&#xD;
          -  Subject who has participated in any other clinical trials within 3 months.&#xD;
&#xD;
          -  Donation or loss of more than 450 mL of blood within 3 months prior to the screening.&#xD;
&#xD;
          -  History of any significant illness in the last four weeks which might confound in the&#xD;
             result of the study or post additional risk in administrating Moxifloxacin to the&#xD;
             subject.&#xD;
&#xD;
          -  Subjects tested positive for syphilis (VDRL) or is known to have serum hepatitis or&#xD;
             carrier of the Hepatitis B surface antigen (HBs Ag) or are carriers of antibodies to&#xD;
             hepatitis C virus (anti-HCV) or to the human immunodeficiency virus (HIV-1 or HIV-2).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pakistani Population</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Bioequivalence Studies and clinical research</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>75270</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Karachi</investigator_affiliation>
    <investigator_full_name>Dr. Muhammad Raza Shah</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Fluoroquinolone</keyword>
  <keyword>Moxifloxacin</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Pakistani Population</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) will only be available to other researchers upon reasonable request to PI keeping the participants' confidentiality intact.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

